Erratum: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells (Diabetologia DOI: 10.1007/s00125-010-1831-8);A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

Diabetologia

Volumn 53, Issue 10, 2010, Pages 2256-2263

  Hattori, Y ^a   Jojima, T ^a   Tomizawa, A ^a   Satoh, H ^a   Hattori, S ^a   Kasai, K ^a   Hayashi, T ^b  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Endothelial cells; GLP 1 NF kB; Nitric oxide

Indexed keywords

CITRULLINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIRAGLUTIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRATE; NITRIC OXIDE; NITRITE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AMINO ACID SYNTHESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 77958052010     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2394-z     Document Type: Erratum

References (24)

1. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3:153-165
2. Irwin DM (2001) Molecular evolution of proglucagon. Regul Pept 98:1-12
3. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340-2350
4. Noyan-Ashraf MH, Momen MA, Ban K et al (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975-983
5. Nyström T, Gutniak MK, Zhang Q et al (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287:E1209-E1215
6. O'Connell KA, Edidin M (1990) A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells. J Immunol 144:521-525
7. Hattori Y, Suzuki M, Hattori S, Kasai K (2002) Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension 39:22-28
8. Pierce JW, Schoenleber R, Jesmok G et al (1997) Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothe- lial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272:21096-21103
9. Giri S, Nath N, Smith B, Viollet B, Singh AK, Singh I (2004) 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP- activated protein kinase. J Neurosci 24:479-487
10. Hattori Y, Suzuki K, Hattori S, Kasai K (2006) Metformin inhibits cytokine-induced NF-ΚB activation via AMPK activation in vascular endothelial cells. Hypertension 47:1183-1188
11. Mayo KE, Miller LJ, Bataille D et al (2003) International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55:167-194
12. Thorens B (1992) Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 89:8641-8645
13. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S (2010) Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 391:1405-1408
14. Buteau J, Foisy S, Joly E, Prentki M (2003) Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52:124-132
15. Daniel EE, Anvari M, Fox-Threlkeld JE, McDonald TJ(2002) Local, exendin-(9-39)-insensitive, site ofaction ofGLP-1 in canine ileum. Am J Physiol Gastrointest Liver Physiol 283:G595-G602
16. Kang JH, Chang SY, Jang HJ et al (2009) Exendin-4 inhibits interleukin-1beta-induced iNOS expression at the protein level, but not at the transcriptional and posttranscriptional levels, in RINm5F beta-cells. J Endocrinol 202:65-75
17. Arakawa M, Mita T, Azuma K et al (2010) Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59:1030-1037
18. Kiefer TJ, Habener JF (1999) The glucagon-like peptides. Endocr Rev 20:876-913
19. Elbrønd B, Jakobsen G, Larsen S et al (2002) Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diab Care 25:1398-1404
20. Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thøgersen H, Wilken M, Johansen NL (2007) Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem 50:6126-6132
21. Kurtzhals P, Havelund S, Jonassen I (1995) Albumin-binding of insulins acylated with fatty acids: characterization of the ligand protein-interaction and correlation between binding-affinity and timing of the insulin effect in-vivo. Biochem J 312:725-731
22. Markussen J, Havelund S, Kurtzhals P et al (1996) Soluble fatty-acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39:281-288
23. Herman GA, Bergman A, Stevens C et al (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91:4612-4619
24. Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M (2006) An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol 46:635-641